✦ LIBER ✦

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

✍ Scribed by Luisa L Villa; Ronaldo LR Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault; Anna R Giuliano; Cosette M Wheeler; Laura A Koutsky; Christian Malm; Matti Lehtinen; Finn Egil Skjeldestad; Sven-Eric Olsson; Margareta Steinwall; Darron R Brown; Robert J Kurman; Brigitte M Ronnett; Mark H Stoler; Alex Ferenczy; Diane M Harper; Gretchen M Tamms; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Frank J Taddeo; Kathrin U Jansen; Mark T Esser; Heather L Sings; Alfred J Saah; Eliav Barr

Book ID: 117783476
Publisher: The Lancet
Year: 2005
Tongue: English
Weight: 109 KB
Volume: 6
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(05)70101-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, immunogenicity, and efficacy of

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women

✍ Gonzalo Perez; Eduardo Lazcano-Ponce; Mauricio Hernandez-Avila; Patricia J. Garc 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB

## Abstract The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective in preventing HPV 6/11/16/18‐related cervical and genital disease in women naï

Efficacy of a prophylactic adjuvanted bi

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

✍ Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Coset 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 151 KB

Impact of a prophylactic quadrivalent hu

Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women

✍ Eliav Barr; Christine K. Gause; Oliver M. Bautista; Radha A. Railkar; Lisa C. Lu 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 185 KB

Efficacy of a bivalent L1 virus-like par

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

✍ Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 185 KB

Safety, immunogenicity, and efficacy of

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

✍ Nubia Muñoz; Ricardo Manalastas Jr; Punee Pitisuttithum; Damrong Tresukosol; Jos 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 171 KB

Efficacy of a quadrivalent prophylactic

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

✍ Elmar A Joura; Sepp Leodolter; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonz 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 165 KB